Supernus Reports Data From Open-Label Phase 2a Study Of SPN-820 In Adults With Major Depressive Disorder; Phase 2a Study Demonstrated Rapid And Substantial Decrease In Depressive Symptoms; SPN-820 Was Well-Tolerated With Few Adverse Events
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals announced positive results from its Phase 2a study of SPN-820 for major depressive disorder, showing rapid and substantial symptom reduction with good tolerability. The company will discuss these results in a webcast, and further Phase 2b results are expected in 2025.
October 17, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Supernus Pharmaceuticals' Phase 2a study of SPN-820 showed rapid and substantial improvement in depressive symptoms with good tolerability, potentially boosting investor confidence and stock price.
The positive results from the Phase 2a study of SPN-820, showing significant improvement in depressive symptoms and good tolerability, are likely to increase investor confidence in Supernus Pharmaceuticals. This could lead to a positive impact on the stock price in the short term, especially with the anticipation of further Phase 2b results in 2025.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100